GARDP Foundation
Overview
-
Posted Opportunities 0
-
Founded Since 2016
Company Description
About GARDP
The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant infections. Together with private, public and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.
GARDP launches new campaign:
#PowerOfAntibiotics
Antibiotic resistance can affect anyone, anywhere
Antibiotic resistance occurs when bacteria change over time and no longer respond to treatment. Millions of people suffer due to antibiotic resistance every year, and nearly 1.3 million people die.
A global crisis of antibiotic resistance
Antibiotic resistance has been identified as one of the top 10 global health threats by the World Health Organization.
Antibiotic resistance is spreading all over the world as a pandemic of drug-resistant infections.
Low- and middle-income countries, and certain population groups like children and the elderly, are hit hardest.
If left unchecked, antibiotic resistance may make it too risky to carry out routine surgeries and other modern medical interventions.
GARDP is acting now to counter drug resistance and save lives
Antimicrobial resistance (including antibiotic resistance) is one of the top 10 global health threats. In 2019, nearly 1.3 million people died as a result of drug-resistant bacterial infections, more than HIV (~860,000) or breast cancer (~700,000). If left unchecked, antibiotic resistance may kill as many as 10 million people each year from 2050.
GARDP’s “5 by 25” initiative aims to deliver five new treatments by 2025 for bacterial infections that pose the greatest threat to human health.
GARDP’s agreements with pharmaceutical and biotech companies have the potential to slash delays in access to antibiotics from decades to years.
GARDP works with governments, the pharmaceutical and biotech industry, academia, and members from civil society around the world.
Bridging antibiotic innovation and access
GARDP develops antibiotics from late-stage clinical trials to the launch of the new drug. 78% of funding for antibiotic development is invested in the early stages. GARDP sustains late-stage development, which is far more expensive.
GARDP improves access to antibiotics for appropriate use for patients in need around the world. Lack of access to novel antibiotics is a global problem. Only 10 of the 25 new antibiotics that entered the market between 1999 and 2014 were registered in more than ten countries. GARDP seeks to expand access in low-, middle-, and high-income countries.
GARDP targets the deadliest pathogens to human health. In 2019, only about 1/3 of antibiotic treatments in preclinical and clinical development had the potential to treat pathogens prioritized by the World Health Organization. In contrast, all of GARDP’s drug development projects target priority pathogens.
GARDP envisions a world in which all infections are treatable for everyone, everywhere.
Responding to a global health crisis: the story of GARDP
The headlines in 2015 were alarming. A deadly superbug was spreading in hospitals in Australia. An outbreak of drug-resistant gonorrhoea threatened public health in England. The superbug “NDM-1” had reached 70 countries. The BBC warned, “Antibiotic resistance: World on cusp of ‘post-antibiotic era’.”
For years, the problem had been growing. Even as bacteria were becoming more and more resistant to antibiotics, pharmaceutical companies were exiting the antibiotic development industry. The work had become more difficult and expensive, so now the risks outweighed the rewards. And the antibiotics that were being introduced were not particularly innovative—there had been no new class of antibiotics in about 30 years.
In this context, the World Health Assembly, the decision-making body of the World Health Organization (WHO), adopted the Global Action Plan on Antimicrobial Resistance (2015).
To deliver on this plan, GARDP was created in 2016 by the WHO and the Drugs for Neglected Disease initiative (DNDi). Like the WHO, GARDP drives a global response to antimicrobial resistance. Like DNDi, GARDP engages in public and private sector partnerships to research and develop new drugs that fit public health needs.
“The rise of drug-resistant bacteria is jeopardizing decades of progress and threatening our ability to prevent and treat infections that were once easy to treat. The Global Antibiotic Research and Development Partnership is an essential element of delivering the Global Action Plan on Antimicrobial Resistance.”
Contact
GARDP Switzerland
Please contact at contact@gardp.org.
Our phone number is +41 22 555 19 90.
Address:
The Global Antibiotic Research and Development Partnership (GARDP)
15 Chemin Camille-Vidart
1202 Geneva
Switzerland
Media queries can be sent to communications@gardp.org.
DNDi-GARDP Southern Africa
Please contact at dndi-gardp-southafrica@dndi.org.
Address:
DNDi-GARDP Southern Africa
Brickfield Canvas, Unit 12, 1st Floor
35 Brickfield Road, Woodstock
Cape Town, 7925
GARDP North America
Please contact at info@gardpna.org and visit gardpna.org.
English